Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-11-28
2011-10-25
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S007100
Reexamination Certificate
active
08044030
ABSTRACT:
The invention encompasses an active metabolite of the 18-membered macrocyclic antimicrobial agents, specifically, a metabolite of tiacumicin B and in certain embodiments, R-Tiacumicin B or and its related compounds. In particular, the invention encompasses a compound that acts as a potent antibiotic agent for the treatment of bacterial infections, specifically GI infections caused by toxin producing strains ofClostridium difficile(C. difficile) andClostridium perfringens(C. perfringens).
REFERENCES:
patent: 3978211 (1976-08-01), Coronelli et al.
patent: 4918174 (1990-04-01), McAlpine et al.
patent: 5583115 (1996-12-01), McAlpine et al.
patent: 5767096 (1998-06-01), Hochlowski et al.
patent: 7378508 (2008-05-01), Chiu et al.
patent: 2006/0257981 (2006-11-01), Shue et al.
patent: 2007/0105791 (2007-05-01), Sears et al.
patent: 2007/0173462 (2007-07-01), Shue et al.
patent: 2007/0259949 (2007-11-01), Chiu et al.
patent: 2008/0194497 (2008-08-01), Chiu et al.
patent: 2008/0269145 (2008-10-01), Shue et al.
patent: 2009/0163428 (2009-06-01), Chiu et al.
patent: 2010/0009925 (2010-01-01), Shue et al.
patent: 2010/0010076 (2010-01-01), Chiu et al.
patent: 2010/0035833 (2010-02-01), Ichikawa et al.
patent: 2010/0081800 (2010-04-01), Chiu et al.
patent: WO 96/35702 (1996-11-01), None
patent: WO 98/02447 (1998-01-01), None
patent: WO 2004/014295 (2004-02-01), None
patent: WO 2005/112990 (2005-12-01), None
patent: WO 2006/085838 (2006-08-01), None
patent: WO 2007/048059 (2007-04-01), None
patent: WO 2008/091518 (2008-07-01), None
patent: WO 2008/091554 (2008-07-01), None
Babakhani et al., “Narrow spectrum activity and low fecal protein binding of Opt-80 and its major hydrolysis metabolite (OP-1118)”, Program and Abstract of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, p. 212 (2007), XP008103008.
Gerber et al., “OPT-80, a macrocyclic antimicrobial agent for the treatment ofClostridium difficileinfections: a review”, Expert Opinion on Investigational Drugs, 17(4), p. 547-53 (2008), XP002479935.
Lewiston et al., “Determination of OPT-80 and its desisobutyryl metabolite (OP-1118) in human plasma by a LC/MS/MS method”, AAPS Journal , American Association of Pharmaceutical Scientists, (2005), XP008103043.
Okumu et al., “Safety and pharmacokinetics of OPT-80, a novel antibiotic for treatment ofClostridium difficileassociated diarrhea (CDAD)”, Program and Abstract of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 204, (2004), XP008103005.
Shangle et al., “Safety and pharmacokinetics of OPT-80 in human volunteers”, Program and Abstract of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, p. 1 (2004), XP008103010.
Shue et al., “Safety, tolerance, and pharmacokinetics studies of OPT-80 in healthy volunteers following single and multiple oral doses”, Antimicrobial Agents and Chemotherapy, 52(4), p. 1391-95 (2008), XP002517908.
Ansel, H.C., Allen, Jr., L.V., Popovich, N.G., Pharmaceutical Dosage Forms and Drug Delivery Systems, published by Lippincott Williams & Wilkins, p. 23-26, 179-180, 196 (1999).
Arnone et al., “Structure Elucidation of the Macrocyclic Antibiotic Lipiarmycin”, Journal of the Chemical Society, Perkin Transactions 1, Chemical Society, pp. 1353-1359 (1987).
Braga et al., “Making Crystals from Crystals: A Green Route to Crystal Engineering and Polymorphism”, Chemical Communications, 3635-3645 (2005).
Caira, M. “Crystalline Polymorphism of Organic Compounds” Topics in Current Chemistry, 198: 163-208 (1998).
Cambridge Crystallographic Data Centre Deposition No. 100349, CCDC No. 114782 (2000).
Chemical Abstracts registry entry 56645-60-4, Tiacumicin B, Copyright 2007, American Chemical Society, pp. 1-2.
Dean, J., Analytical Chemistry Handbood, published 1995 by McGraw-Hill, Inc., pp. 10.23-10.26.
Finegold et al. “In vitro activities of OPT-80 and comparator drugs against intestinal bacteria” Antimicrobial Agents and Chemotherapy 48(12): 4898-4902 (2004).
Gerding et al. “Clostridium difficile-associated diarrhea and colitis” Infection Control and Hospital Epidemiology 16(8):459-477 (1995).
Hochlowski et al.: “Tiacumicins a Novel Complex of 18-Membered Macrolides II. Isolation and Structure Determination”, J. of Anti., Japan Anti. Res. Assn., p. 575-588 (1987).
Jain et al., Polymorphism in Pharmacy, Indian Drugs, vol. 23(6), pp. 315-329 (1986).
Morissette et al. “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids” Advanced Drug Delivery Reviews 56(3):275-300 (2004).
Pharmaceutical Dosage Forms: Tablets, vol. 2, published 1990 by Marcel Dekker, Inc., ed. by Lieberman, Lachman, and Schwartz, pp. 462-472.
Poduval et al. “Clostridium difficileand vancomycin-resistant enterococcus: the new nosocomial alliance” The American Journal of Gastroenterology 95(12):3513-3515 (2000).
Polymorphism in Pharmaceutical Solids, published 1999 by Marcel Dekker Inc., ed. by Harry G. Brittain, pp. 1-2.
Swanson et al., “In vitro and in vivo evaluation of tiacumicins B and C againstClostridium difficile”, Antimicrob. Agents Chemother., 35(6): 1108-1111 (1991).
The Condensed Chemical Dictionary, Tenth Edition, published 1981 by the Van Nostrand Reinhold Company, revised by Gessner G. Hawley, p. 35 and 835.
Theriault et al. “Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation . . . ” J Antibiot (Tokyo) 40(5):567-574 (1987).
Vippagunta et al. “Crystalline solids” Advanced Drug Delivery Reviews 48:3-26 (2001).
Cavalleri et al. “Structure and biological activity of lipiarmycin B,” The Journal of Antibiotics, 1988, 41(3): 308-315.
Credito et al., “Antianaerobic Activity of OPT 80 Compared to Other Agents,” Hershey Medical Center Department of Pathology, (poster), 44th ICAAC (Oct. 30-Nov. 2, 2004).
Remington: The Science and Practice of Pharmacy, published 2000 by Lippincott Williams and Wilkins, pp. 802-803.
Ackerman et al., “In vitro activity of OPT-80 againstClostridium difficile,” Antimicrobial Agents and Chemotherapy, 2004, 48(6), pp. 2280-2282.
Credito et al., “Activity of OPT-80, a Novel Macrocycle, Compared with Those of Eight Other Agents against Selected Anaerobic Species”, Antimicrobial Agents & Chemotherapy, 48(11), pp. 4430-4434 (2004).
K.L. Credito, P.C. Appelbaum, “Antianaerobic Activity of OPT 80 Compared to Other Agents,” Hershey Medical Center Department of Pathology, (poster), 44th ICAAC (Oct. 30-Nov. 2, 2004) in Chicago.
Babakhani Farah Kondori
Chiu Yu-Hung
Ichikawa Yoshi
Shue Youe-Kong
Morgan & Lewis & Bockius, LLP
Optimer Pharmaceuticals, Inc.
Peselev Elli
LandOfFree
Antibiotic macrocycle compounds and methods of manufacture... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibiotic macrocycle compounds and methods of manufacture..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibiotic macrocycle compounds and methods of manufacture... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4286724